31.23
31.23 (0.76%)
As of Feb 26, 2024
Immunogen, Inc. [IMGN]
Source:
Company Overview
We are a clinical-stage biotechnology company focused on developing the next generation of ADCs to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer patients more good days. We call this our commitment to “target a better now.”
| Country | United States |
| Headquarters | waltham, massachusetts |
| Phone Number | (781)895-0600 |
| Industry | manufacturing |
| CEO | Mark J. Enyedy |
| Website | www.clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $113.4 |
| Operating Profit | $26 |
| Net Income | $30.7 |
| Net Cash | $330.4 |
Profit Ratios
| Gross Margin | $111.3 |
| Operating Margin | 22.9 |
| Profit as % of Revenues | 98.1% |
| Profit as % of Assets | 0% |
| Profit as % of Stockholder Equity | 0% |
Management Effectiveness
| Return on Equity | 0% |
| Return on Assets | 0% |
| Turnover Ratio | 0% |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $822.1 |
| Total Liabilities | $260.5 |
| Operating Cash Flow | $-137.7 |
| Investing Cash Flow | $-1.6 |
| Financing Cash Flow | $469.7 |
